Mitchell DA - Search Results

1

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH. Batich KA, et al. Among authors: mitchell da. Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057. Clin Cancer Res. 2017. PMID: 28411277 Free PMC article. Clinical Trial.

2

Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.

Mitchell DA, Nair SK, Gilboa E. Mitchell DA, et al. Eur J Immunol. 1998 Jun;28(6):1923-33. doi: 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9. Eur J Immunol. 1998. PMID: 9645374 Free article.

3

Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.

Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. Nair S, et al. Among authors: mitchell da. J Immunol. 1999 Jun 1;162(11):6426-32. J Immunol. 1999. PMID: 10352256

4

RNA-transfected dendritic cells in cancer immunotherapy.

Mitchell DA, Nair SK. Mitchell DA, et al. J Clin Invest. 2000 Nov;106(9):1065-9. doi: 10.1172/JCI11405. J Clin Invest. 2000. PMID: 11067858 Free PMC article. Review. No abstract available.

5

RNA transfected dendritic cells as cancer vaccines.

Mitchell DA, Nair SK. Mitchell DA, et al. Curr Opin Mol Ther. 2000 Apr;2(2):176-81. Curr Opin Mol Ther. 2000. PMID: 11249639 Review.

6

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. Fecci PE, et al. Among authors: mitchell da. J Neurooncol. 2003 Aug-Sep;64(1-2):161-76. doi: 10.1007/BF02700031. J Neurooncol. 2003. PMID: 12952297 Review.

7

Adoptive immunotherapy for malignant glioma.

Mitchell DA, Fecci PE, Sampson JH. Mitchell DA, et al. Cancer J. 2003 May-Jun;9(3):157-66. doi: 10.1097/00130404-200305000-00004. Cancer J. 2003. PMID: 12952301 Review.

8

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH. Fecci PE, et al. Among authors: mitchell da. Cancer Res. 2006 Mar 15;66(6):3294-302. doi: 10.1158/0008-5472.CAN-05-3773. Cancer Res. 2006. PMID: 16540683

9

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.

Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, Mitchell DA, Cui X, Cummings TJ, Bigner DD, Gilboa E, Sampson JH. Fecci PE, et al. Among authors: mitchell da. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305. doi: 10.1158/1078-0432.CCR-06-0053. Clin Cancer Res. 2006. PMID: 16857805

10

Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.

Learn CA, Grossi PM, Schmittling RJ, Xie W, Mitchell DA, Karikari I, Wei Z, Dressman H, Sampson JH. Learn CA, et al. Among authors: mitchell da. J Neuroimmunol. 2007 Jan;182(1-2):63-72. doi: 10.1016/j.jneuroim.2006.09.016. Epub 2006 Nov 29. J Neuroimmunol. 2007. PMID: 17137636 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

598 results

Search Page

Filters